{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:34:11Z","timestamp":1747182851555,"version":"3.40.5"},"reference-count":42,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aims<\/jats:title><jats:p>In Australia, patterns of use of smoking cessation medications and factors associated with their dispensing are currently not known. This study aimed to measure the demographic and clinical factors associated with varenicline dispensing compared with nicotine replacement therapy (NRT) and bupropion among first\u2010time users of Pharmaceutical Benefits Scheme (PBS) subsidised smoking cessation medicines in Australia and to characterise those who discontinued varenicline treatment prematurely.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective, population\u2010based study. Logistic regression was used to identify factors associated with varenicline dispensing compared with NRT and bupropion. Sensitivity analyses estimated the proportion of individuals who completed the recommended 12\u2009weeks of varenicline treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting and participants<\/jats:title><jats:p>First\u2010time users of PBS subsidised smoking cessation medicines in Australia. Individuals first dispensed a smoking cessation medicine between 2011 and 2019 were identified from a 10% random sample of the national dispensing claims data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>The outcome for the regression analysis was the dispensing of varenicline compared with NRT and bupropion. The dispensing of a smoking cessation medicine was identified using the World Health Organization Anatomical Therapeutic Chemical Classification System and PBS item codes. Independent variables included demographic and clinical characteristics such as sex, age, concessional status, year of treatment initiation and comorbidities identified using the Rx\u2010Risk index. The proportion of people who discontinued varenicline treatment after the initiation pack was determined using prescription refill data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>A total of 94\u2009532 people had their first PBS subsidised smoking cessation medicine. Of these, 62\u2009367 (66.0%) were dispensed varenicline, 29\u2009949 (31.7%) NRT and 2216 (2.3%) bupropion. The odds of varenicline dispensing were higher in males (OR, 1.18; 95% CI, 1.14\u20131.21), but lower in older adults (0.86 [0.82\u20130.90] in above 30\u2009years to 0.49 [0.47\u20130.52] in 61\u2009years and above), among concession beneficiaries (0.44; 0.43\u20130.46), and those with congestive heart failure (0.60; 0.53\u20130.68), depression (0.61; 0.54\u20130.69), anxiety (0.70; 0.66\u20130.73), psychotic illness (0.39; 0.37\u20130.42), and chronic obstructive pulmonary disease (0.87; 0.82\u20130.92). The majority (37\u2009670; 60.4%) of those dispensed varenicline discontinued treatment after the initiation pack. Anxiety and psychotic illnesses were significantly more prevalent in those who discontinued treatment. Only 2804 (4.5%) of those dispensed varenicline completed 12\u2009weeks of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Individuals dispensed varenicline in Australia appear to be healthier compared with those who are dispensed nicotine replacement therapy or bupropion.<\/jats:p><\/jats:sec>","DOI":"10.1111\/add.15949","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T10:34:51Z","timestamp":1653302091000},"page":"2683-2694","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterising the use of varenicline: an analysis of the Australian dispensing claims data"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7027-7887","authenticated-orcid":false,"given":"Rukshar K.","family":"Gobarani","sequence":"first","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-9441","authenticated-orcid":false,"given":"Jenni","family":"Ilom\u00e4ki","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Victoria Australia"},{"name":"School of Public Health and Preventive Medicine Monash University  Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6910-9907","authenticated-orcid":false,"given":"Stephen","family":"Wood","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9954-0538","authenticated-orcid":false,"given":"Michael J.","family":"Abramson","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine Monash University  Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8505-622X","authenticated-orcid":false,"given":"Billie","family":"Bonevski","sequence":"additional","affiliation":[{"name":"Discipline Lead and Discipline Group Lead, College of Medicine and Public Health Flinders University  Adelaide Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0326-0495","authenticated-orcid":false,"given":"Johnson","family":"George","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Victoria Australia"},{"name":"School of Public Health and Preventive Medicine Monash University  Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,6,11]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization.Tobacco 2020. [Accessed on: 3\/03\/2021]. Available from:https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tobacco"},{"volume-title":"Alcohol, tobacco & other drugs in Australia","year":"2019","author":"Australian Institute of Health and Welfare","key":"e_1_2_10_3_1"},{"key":"e_1_2_10_4_1","article-title":"Pharmacological interventions for smoking cessation: An overview and network meta\u2010analysis","volume":"5","author":"Cahill K","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.18332\/tid\/94212"},{"issue":"6","key":"e_1_2_10_6_1","first-page":"592","article-title":"Association of out\u2010of\u2010Pocket Pharmacy Costs with adherence to Varenicline","volume":"20","author":"Suehs BT","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886311207040282"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntr003"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.03.021"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2016.02.018"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12778"},{"key":"e_1_2_10_12_1","unstructured":"U.S. Food and Drug Administration.Public health advisory: important information on Chantix (varenicline) 2008. [Accessed on: 22\/12\/2019] Available from:http:\/\/wayback.archive-it.org\/7993\/20170112032505\/http:\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm051136.htm"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13592"},{"key":"e_1_2_10_14_1","unstructured":"U.S. Food and Drug Administration.FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease 2011. [Accessed on: 01 January 2020] Available from:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-chantix-varenicline-may-increase-risk-certain-cardiovascular-adverse#data"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30272-0"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1109"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.0397"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.64"},{"key":"e_1_2_10_19_1","article-title":"Relapse prevention interventions for smoking cessation","volume":"10","author":"Livingstone\u2010Banks J","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pon.4978"},{"key":"e_1_2_10_21_1","unstructured":"Australian Government Department of Health.Schedule of Pharmaceutical Benefits General Pharmacuetical Schedule \u2010 Volume 1. 2021. Available from:https:\/\/www.pbs.gov.au"},{"volume-title":"Post\u2010market review of medicines for smoking cessation","year":"2021","author":"Pharmaceutical Benefits Advisory Committee","key":"e_1_2_10_22_1"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.17061\/phrp2541546"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021122"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118548387"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntz223"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/geronb\/52B.4.S212"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-14-1024"},{"issue":"9","key":"e_1_2_10_30_1","article-title":"Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications","volume":"2","author":"Desai RJ","year":"2019","journal-title":"JAMA"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001015"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.67.4.555"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntu212"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/14622200802097506"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00845.x"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntv207"},{"key":"e_1_2_10_37_1","unstructured":"Pharmaceutical Benefits Scheme.Post\u2010market review of medicines used for smoking cessation: Report to PBAC: Background.; 2021. Available from:https:\/\/www.pbs.gov.au\/info\/reviews\/public-consultation-on-the-post-market-review-of-medicines"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1670"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntq215"},{"key":"e_1_2_10_40_1","unstructured":"Centers for Disease Control and Prevention.Tobacco use and quitting among individuals with behavioral health conditions updated 4 February 2020. [Accessed on: 29 October 2020] Available from:https:\/\/www.cdc.gov\/tobacco\/disparities\/mental-illness-substance-use\/index.htm"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038184"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7195"},{"issue":"5","key":"e_1_2_10_43_1","first-page":"344","article-title":"Primary non\u2010adherence of prescribed pharmaceutical treatments and interventions: An investigative review to improve quality in primary care","volume":"25","author":"Seal F","year":"2017","journal-title":"Qual Prim Care"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.15949","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:25:28Z","timestamp":1692671128000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.15949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,11]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/add.15949"],"URL":"https:\/\/doi.org\/10.1111\/add.15949","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"type":"print","value":"0965-2140"},{"type":"electronic","value":"1360-0443"}],"subject":[],"published":{"date-parts":[[2022,6,11]]},"assertion":[{"value":"2021-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}